SOLICITATION NOTICE
B -- Laboratory Testing for GBV-C Infection & Risk of the NHL in the PLCO Cohort.
- Notice Date
- 3/23/2011
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-110049-MW
- Archive Date
- 4/21/2011
- Point of Contact
- Melissa R. Ward, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
wardmr@mail.nih.gov, cr214i@nih.gov
(wardmr@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6072, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics (DCEG) plans to procure on a sole source bases with the University of Iowa, 200 Hawkins Dr., UIHC, Iowa City, IA 52242 for laboratory testing for GBV-C Infection & Risk of the NHL in the PLCO Cohort. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 541380 and the business size standard in $12M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price Indefinite Delivery Indefinite Quantity (IDIQ) type contract. Period of Performance: Performance shall be for twelve months from date of award with one twelve month option period. To investigate the association between GB virus C (GBV-C) and risk of non-Hodgkin lymphoma (NHL), NCI investigators are conducting a nested case-control study of GBV-C and NHL in the Prostate, Lung, Colorectal and Ovarian (PLCO) study population. The purpose of the procurement is to provide laboratory testing for GBV-C to support NCI's case-control study of non-Hodgkin lymphoma. This study has three aims: 1) to evaluate whether the prevalence of active GBV-C infection, as indicated by detection of circulating RNA, is greater in cases compared to controls; 2) to evaluate persistence of GBV-C infection in cases and controls; and 3) to evaluate whether the prevalence of past GBV-C infection, as indicated by the detection of GBV-C antibody, is greater in cases than in controls. The contractor shall perform: 1) GBV-C RNA testing in serum samples using RT-PCR; 2) E2 antibody testing in serum samples using ELISA; and 3) HCV and HIV antibody testing in serum samples using ELISA. Due to the lack of an approved or commercial test for GBV-C RNA and E2 antibody, it is necessary for NCI to purchase testing from a research laboratory. The Stapleton laboratory at the University of Iowa has developed and optimized RT-PCR methods for GB virus type C, as well as an antibody capture ELISA method based on a recombinant GBV-C E2 protein expression system. Since 1999, this laboratory has tested more than 8,000 samples from 18 cohorts including several large multicenter study groups. No other known laboratory has developed and validated GBV-C tests. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on April 6, 2011. No electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Ward, Contract Specialist, atwardmr@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-110049-MW on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110049-MW/listing.html)
- Record
- SN02407906-W 20110325/110323234827-fbafa0eea8870a33a8e30f50b3e6576e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |